Levosimendan vs. Milrinone in cardiac surgery: A GRADE-assessed systematic review and meta-analysis
European Journal of Clinical Pharmacology · 2026
DOI: 10.1007/s00228-025-03958-9 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift European Journal of Clinical Pharmacology, 2026. Verfasst von Ahmed Emara und 10 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Al-Azhar University, Cairo, Egypt. emara9055@gmail.com. Hauptthemen laut MEDLINE: Simendan, Milrinone, Cardiac Surgical Procedures, Cardiotonic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 54 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Levosimendan and Milrinone are commonly used inotropic agents in patients undergoing cardiac surgery; there is a lack of evidence regarding the comparative safety and efficacy of both drugs. We aim to compare the clinical efficacy and safety of levosimendan versus Milrinone in these patients. METHODS: We conducted a systematic review and meta-analysis following PRISMA guidelines. PubMed, Scopus, Web of Science, and Cochrane Central were searched up to November 30, 2024, for studies comparing levosimendan and Milrinone in adult and pediatric cardiac surgery patients. We used R statistical software to pool dichotomous data using odds ratio (OR) and continuous data using mean difference (MD) with a 95% confidence interval (CI). RESULTS: Seventeen studies (15 RCTs and 2 observational) involving 890 patients were included. Across all efficacy outcomes, including cardiac index (MD 0.02, 95% CI -0.15-0.19), mean arterial pressure (MAP) (MD -0.09, 95% CI -1.97-1.79), and mPAP (mean pulmonary artery pressure) (MD -0.88, 95% CI -2.66, 0.89), no significant differences were found between the two drugs (P > 0.05). Safety outcomes, including all-cause mortality (OR 0.97, 95% CI 0.48-1.93), acute kidney injury (OR 0.89, 95% CI 0.55-1.44), and arrhythmias (OR 0.87, 95% CI 0.41-1.88), showed no statistically significant differences (P > 0.05). CONCLUSION: Levosimendan and Milrinone showed no significant differences in efficacy or safety in cardiac surgery patients. However, wide confidence intervals indicate potential clinically relevant effects. Current evidence does not favor any single agent universally, supporting individualized use based on patient phenotype and institutional practice. Further high-quality trials are needed to confirm.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, Al-Azhar University, Cairo, Egypt. emara9055@gmail.com.
- Faculty of Medicine, Sohag University, Sohag, Egypt.
- Clinical Research Department, El-Gomhoria General Hospital, Ministry of Health and Population, Alexandria, Egypt.
- Medical Research Group of Egypt (MRGE), Negida Academy, Arlington, MA, USA.
- Department of Internal Medicine, Mercy Health- The Jewish hospital, Cincinnati, OH, USA.
- Faculty of Medicine, King Edward Medical University, Lahore, Pakistan.
Zitieren
APA
Emara, A., Ellebedy, M., Aboeldahab, H., Nazir, A., Elgendy, M. S., Hassan, A. M., Barakat, Y., Saad, O. A., Elawady, A., Elnady, M., & Abdelaziz, A. (2026). Levosimendan vs. Milrinone in cardiac surgery: A GRADE-assessed systematic review and meta-analysis. European Journal of Clinical Pharmacology. https://doi.org/10.1007/s00228-025-03958-9
Vancouver
Emara A, Ellebedy M, Aboeldahab H, Nazir A, Elgendy MS, Hassan AM, et al. Levosimendan vs. Milrinone in cardiac surgery: A GRADE-assessed systematic review and meta-analysis. European Journal of Clinical Pharmacology. 2026. doi:10.1007/s00228-025-03958-9
BibTeX
@article{Emara2026,
author = {Emara, Ahmed and Ellebedy, Mohamed and Aboeldahab, Heba and Nazir, Abubakar and Elgendy, Mohamed S and Hassan, Ahmed Magdy and Barakat, Youssef and Saad, Omar Abdulrahman and Elawady, Aliaa and Elnady, Mohamed and Abdelaziz, Ahmed},
title = {Levosimendan vs. Milrinone in cardiac surgery: A GRADE-assessed systematic review and meta-analysis},
journal = {European Journal of Clinical Pharmacology},
year = {2026},
doi = {10.1007/s00228-025-03958-9}
}
EUVIMED